Literature DB >> 26882812

The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin.

Huseyin Tugrul Çelik, Nermin Akkaya, Husamettin Erdamar, Sumeyye Gok, Fatmanur Kazanci, Bora Demircelik, Muzaffer Cakmak, Ramazan Yigitoglu.   

Abstract

BACKGROUND: Hypertension and obesity are two major threats for public health. Up to the present, antihypertensive medications have been used to lower blood pressure, which seem to provide a better life with lower morbidity and mortality rates. Their effect on etiopathogenesis of hypertension is now an area of developing research. The association between hypertension and obesity also suggests the link between antihypertensive agents and energy hemostasis. We aimed to investigate the effects of antihypertensive treatment on the irisin, adropin, and perilipin levels in patients with essential hypertension and to compare them with healthy volunteers in terms of their effect on energy hemostasis.
METHODS: In total, 85 newly diagnosed patients with untreated essential hypertension were admitted to the outpatient clinic. Patients were randomized to one of the following treatment protocols: amlodipine or valsartan for a 12 week period. 42 patients were randomized into the valsartan group and 43 patients into the amlodipine group. Serum perilipin, irisin, and adropin levels were measured before and after drug treatment by ELISA kits.
RESULTS: We discovered that the hypertensive patients have lower levels of perilipin and higher levels of adropin compared with the control group. Both amlodipine and valsartan increased the levels of perilipin, irisin, and adropin after 12 weeks of treatment.
CONCLUSIONS: In conclusion, in regulating energy balance, perilipin, irisin, and adropin, could be of pathogenic importance in obesity-induced hypertension. Hence, ongoing trials need to elucidate this mechanism.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26882812     DOI: 10.7754/clin.lab.2015.150420

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  8 in total

1.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

2.  Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation.

Authors:  Kengo Sato; Tomoyuki Yamashita; Remina Shirai; Koichiro Shibata; Taisuke Okano; Maho Yamaguchi; Yusaku Mori; Tsutomu Hirano; Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

Review 3.  Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research.

Authors:  Mariami Jasaszwili; Maria Billert; Mathias Z Strowski; Krzysztof W Nowak; Marek Skrzypski
Journal:  Molecules       Date:  2020-01-27       Impact factor: 4.411

4.  The Role of Myokines and Adipokines in Hypertension and Hypertension-related Complications.

Authors:  Ken Chen; Mengdi Zhou; Xiaomei Wang; Shuang Li; Dachun Yang
Journal:  Hypertens Res       Date:  2019-05-27       Impact factor: 3.872

Review 5.  The Emerging Role of Irisin in Cardiovascular Diseases.

Authors:  Jinjuan Fu; Fangtang Li; Yuanjuan Tang; Lin Cai; Chunyu Zeng; Yongjian Yang; Jian Yang
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

Review 6.  Irisin, an Effective Treatment for Cardiovascular Diseases?

Authors:  Chen Liu; Aili Wei; Tianhui Wang
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-13

Review 7.  Adropin: a hepatokine modulator of vascular function and cardiac fuel metabolism.

Authors:  Bellina A S Mushala; Iain Scott
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-20       Impact factor: 4.733

8.  Adropin Serum Levels in Patients with Primary Sjögren's Syndrome.

Authors:  Marijana Janković Danolić; Dijana Perković; Marin Petrić; Igor Barišić; Katarina Gugo; Joško Božić
Journal:  Biomolecules       Date:  2021-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.